Jacobsen E A, Doyle A D, Colbert D C, Zellner K R, Protheroe C A, LeSuer W E, Lee N A, Lee J J
Division of Pulmonary Medicine, Department of Biochemistry and Molecular Biology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA.
Division of Hematology/Oncology, Department of Biochemistry and Molecular Biology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA.
Allergy. 2015 Sep;70(9):1148-59. doi: 10.1111/all.12655. Epub 2015 Jun 14.
Eosinophils are hallmark cells of allergic Th2 respiratory inflammation. However, the relative importance of eosinophil activation and the induction of effector functions such as the expression of IL-13 to allergic Th2 pulmonary disease remain to be defined.
Wild-type or cytokine-deficient (IL-13(-/-) or IL-4(-/-) ) eosinophils treated with cytokines (GM-CSF, IL-4, IL-33) were adoptively transferred into eosinophil-deficient recipient mice subjected to allergen provocation using established models of respiratory inflammation. Allergen-induced pulmonary changes were assessed.
In contrast to the transfer of untreated blood eosinophils to the lungs of recipient eosinophil deficient mice, which induced no immune/inflammatory changes either in the lung or in the lung draining lymph nodes (LDLN), pretreatment of blood eosinophils with GM-CSF prior to transfer elicited trafficking of these eosinophils to LDLN. In turn, these LDLN eosinophils elicited the accumulation of dendritic cells and CD4(+) T cells to these same LDLNs without inducing pulmonary inflammation. However, exposure of eosinophils to GM-CSF, IL-4, and IL-33 prior to transfer induced not only immune events in the LDLN, but also allergen-mediated increases in airway Th2 cytokine/chemokine levels, the subsequent accumulation of CD4(+) T cells as well as alternatively activated (M2) macrophages, and the induction of pulmonary histopathologies. Significantly, this allergic respiratory inflammation was dependent on eosinophil-derived IL-13, whereas IL-4 expression by eosinophils had no significant role.
The data demonstrate the differential activation of eosinophils as a function of cytokine exposure and suggest that eosinophil-specific IL-13 expression by activated cells is a necessary component of the subsequent allergic Th2 pulmonary pathologies.
嗜酸性粒细胞是过敏性Th2型呼吸道炎症的标志性细胞。然而,嗜酸性粒细胞活化以及效应功能(如白细胞介素-13表达)的诱导在过敏性Th2型肺部疾病中的相对重要性仍有待确定。
使用已建立的呼吸道炎症模型,将经细胞因子(粒细胞-巨噬细胞集落刺激因子、白细胞介素-4、白细胞介素-33)处理的野生型或细胞因子缺陷型(白细胞介素-13基因敲除或白细胞介素-4基因敲除)嗜酸性粒细胞过继转移到嗜酸性粒细胞缺陷的受体小鼠体内,使其遭受过敏原激发。评估过敏原诱导的肺部变化。
与将未经处理的血液嗜酸性粒细胞转移到嗜酸性粒细胞缺陷的受体小鼠肺部不同,后者在肺部或肺引流淋巴结中未诱导免疫/炎症变化,在转移前用粒细胞-巨噬细胞集落刺激因子预处理血液嗜酸性粒细胞会促使这些嗜酸性粒细胞向肺引流淋巴结迁移。反过来,这些肺引流淋巴结中的嗜酸性粒细胞促使树突状细胞和CD4(+) T细胞在相同的肺引流淋巴结中积聚,而不诱导肺部炎症。然而,在转移前将嗜酸性粒细胞暴露于粒细胞-巨噬细胞集落刺激因子、白细胞介素-4和白细胞介素-33不仅会在肺引流淋巴结中引发免疫事件,还会导致过敏原介导的气道Th2型细胞因子/趋化因子水平升高、随后CD4(+) T细胞以及替代性活化(M2)巨噬细胞的积聚,以及肺部组织病理学变化。值得注意的是,这种过敏性呼吸道炎症依赖于嗜酸性粒细胞衍生的白细胞介素-13,而嗜酸性粒细胞表达白细胞介素-4则没有显著作用。
数据表明嗜酸性粒细胞的活化因细胞因子暴露而存在差异,并提示活化细胞中嗜酸性粒细胞特异性白细胞介素-13的表达是随后过敏性Th2型肺部病理变化的必要组成部分。